Barclays upgraded Aveanna (AVAH) to Overweight from Equal Weight with a price target of $9.50, up from $5.50. The company reported a “thesis changing quarter” that erased concerns over regulation, the analyst tells investors in a research note. The firm says Aveanna showed “positive differentiation” within the Medicaid landscape, prompting materially higher earnings estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH:
- Aveanna Healthcare’s Earnings Call Highlights Growth and Optimism
- Aveanna price target raised to $6.75 from $5 at UBS
- Aveanna upgraded to Outperform from Market Perform at Raymond James
- Aveanna Healthcare Highlights Strong Financial Performance
- Aveanna Healthcare Reports Strong Q2 Growth and Raises 2025 Outlook